THE RELATIONSHIP OF P53 IMMUNOSTAINING TO SURVIVAL IN CARCINOMA OF THE LUNG

Creative Commons License

MCLAREN R., KUZU I., DUNNILL M., HARRIS A., LANE D., GATTER K.

BRITISH JOURNAL OF CANCER, cilt.66, sa.4, ss.735-738, 1992 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 66 Sayı: 4
  • Basım Tarihi: 1992
  • Doi Numarası: 10.1038/bjc.1992.348
  • Dergi Adı: BRITISH JOURNAL OF CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.735-738
  • Ankara Üniversitesi Adresli: Hayır

Özet

In this study 125 primary lung tumours have been immunostained with a panel of 5 anti-p53 antibodies (PAb240, PAb421, PAb1801, CM-1 and C19). These antibodies recognise different epitopes over the full extent of the p53 gene, It is generally believed that immunolabelling identifies only mutant p53 proteins due to the short half life of the wild type protein. The aims of this study were to confirm earlier studies of p53 positivity in human lung tumours and to establish whether or not this bore any relationship to survival.